Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM

Video

In Partnership With:

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Doris Hansen, MD, assistant member, Moffitt Cancer Center department of blood and marrow transplant and cellular immunotherapy, discusses the progression-free survival (PFS) benefit yielded by idecabtagene vicleucel (ide-cel; Abecma) on the phase 2 KarMMa trial (NCT03361748) in patients with pretreated relapsed/refractory multiple myeloma.

The phase 2 KarMMa trial (NCT03361748) demonstrated an overall response rate of 73% in all patients treated with ide-cel and the median PFS was 8.6 months in patients with R/R MM.

The study examined the safety and efficacy of ide-cel in this patient population and was pivotal because it provided a new novel therapy to those who otherwise have limited options, according to Hansen. Patients with relapsed/refractory multiple myeloma often have a median PFS of 2 to 3 months, according to Hansen. However, patients who receive a BCMA-targeted CAR T-cell therapy experience improved outcomes, Hansen continues.

For example, results from the KarMMa study showed that patients who achieved a deep response with ide-cel, or a complete remission or better, had a median PFS of approximately 22 months, and a duration of response of 21 months. These results held up with a longer follow-up, Hansen concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
A panel of 4 experts on hematologic malignancies